Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens

NCT05216510 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy

Conditions

Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2

Interventions

BIOLOGICAL: TNX-2110
BIOLOGICAL: TNX-2120
BIOLOGICAL: TNX-2130
BIOLOGICAL: CANDIN
BIOLOGICAL: Diluent

Sponsor

Tonix Pharmaceuticals, Inc.

Collaborators

[object Object]